Studies in humans treating brain metastases from either EGFR mutant lung cancers or HER2-overexpressing breast cancers demonstrated that pulsatile weekly dosing with erlotinib or lapatinib, at up to 7-fold the standard daily dose, was effective and paradoxically caused less toxicity than daily dosing. The gene discussed is EGFR; the disease is breast cancer.